AMD POC Diagnostic
Age-related Macular Degeneration (AMD)
ResearchActive
Key Facts
About maintect
maintect is a private, preclinical-stage biotech based in Mainz, Germany, founded in 2018. The company pursues a dual business model: providing contract research services for lateral flow assay (LFA) and antibody drug development, and driving its own proprietary programs in ophthalmic diagnostics and therapeutics for AMD. Its core strategy leverages expertise in immunochromatography and antibody engineering to address significant unmet needs in both the diagnostics and therapeutics markets for retinal diseases.
View full company profileTherapeutic Areas
Other Age-related Macular Degeneration (AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed AMD Program | Character Biosciences | Research |
| SYL1801 | Sylentis | Phase 2a |
| Biosimilar Ranibizumab | Paras Biopharmaceuticals Finland | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |